Ligand-based design and synthesis of new trityl histamine and trityl cysteamine derivatives as SIRT2 inhibitors for cancer therapy
This study presents an extensive SAR study of our reported trityl scaffold-based SIRT2 inhibitors. This study encompasses a range of different medicinal chemistry approaches to improve the activity of the lead compounds TH-3 and STCY1. The rationally designed and synthesized structures were confirmed using NMR and high-resolution mass spectroscopy before performing SIRT2 inhibition assay, NCI60 cytotoxicity test, and cell cycle analysis. Indeed, our strategies afforded hitherto unreported SIRT2 inhibitors with high activity, particularly 2a, 4a, 7c, and 7f. Remarkably, the presence of a lipophilic para substitution on the phenyl group of a freely rotating or a locked trityl moiety enhanced activity SIRT2 inhibition. Concomitantly, the synthesized compounds showed prominent activity against different cancer lines from the NCI60 assay. Of interest, compound 7c stands out as a potent and highly selective antiproliferative agent against leukemia and colon cancer panels. Furthermore, 7c treatment resulted in cell cycle arrest in MCF-7 cells at G2 phase and did not cause in vitro DNA cleavage.PMID:38484678 | DOI:10.1016/j.ejmech.2024.116302
Source: European Journal of Medicinal Chemistry - Category: Chemistry Authors: Mostafa M Badran Samar H Abbas Hiroshi Tateishi Yuki Maemoto Tsugumasa Toma Akihiro Ito Mikako Fujita Masami Otsuka Mohamed Abdel-Aziz Mohamed O Radwan Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Chemistry | Colon Cancer | Colorectal Cancer | Leukemia | Study